Analystreport

Novelion Therapeutics (NASDAQ: NVLN) had its price target lowered by analysts at Royal Bank of Canada from $7.00 to $6.00. They now have a "sector perform" rating on the stock.

NOVELION THERAPEUTICS INC COMMON SHARES  (NVLN) 
Last novelion therapeutics inc common shares earnings: 5/7 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.novelion.com